Chanjo ya Pamoja ya Homa ya Ini A+B

Wasafiri wa kimataifa:

• Wasafiri wanaohitaji kinga ya homa ya ini A na B — rahisi kupata chanjo moja badala ya mbili

• Hasa wasafiri wanaokwenda maeneo yenye kiwango cha juu cha maambukizi ya zote mbili

Vikundi vyenye hatari:

• Wahudumu wa afya

• Watu wenye magonjwa sugu ya ini

• Watumiaji wa dawa za kujidunga

• Watu wenye wenzi wengi wa kingono

• Wafanyakazi wa sekta ya chakula

Faida:

• Sindano 3-4 badala ya 5 (chanjo mbili tofauti)

• Ratiba ya haraka inapatikana (siku 0, 7, 21 + nyongeza miezi 12)

Kizuizi kamili:

• Mzio mkubwa kwa kiungo chochote cha chanjo (pamoja na chachu, neomycin)

• Mzio mkubwa kwa dozi ya awali ya chanjo ya homa ya ini A au B

Si kizuizi:

• Ujauzito — chanjo isiyohai; inaweza kutolewa ikiwa hatari ipo

• Kunyonyesha — salama

• VVU — inashauriwa; mwitikio unaweza kuwa dhaifu

Athari za kawaida:

• Maumivu kwenye sehemu ya sindano — 35-55%

• Uchovu — 15-20%

• Maumivu ya kichwa — 10-15%

• Homa nyepesi — 3-5%

Athari mfumo wa athari ni sawa na chanjo za homa ya ini A na B zilizotolewa kando:

• Hakuna athari za ziada zinazojulikana kutokana na mchanganyiko

• Usalama mzuri — miaka mingi ya matumizi duniani

Ratiba ya kawaida:

• Dozi 3 za 1.0 ml kwa sindano ya misuli (IM) katika deltoid

• Ratiba: miezi 0, 1, 6

Ratiba ya haraka kwa wasafiri:

• Dozi 4: siku ya 0, 7, 21-30 + nyongeza miezi 12

• Inatoa kinga ya awali ndani ya wiki 3

Umri:

• ≥miaka 1 (kipimo cha watoto) au ≥miaka 16 (kipimo cha watu wazima)

Kwa watu wenye VVU:

• Mwitikio unaweza kuwa dhaifu — fikiria kupima anti-HBs na anti-HAV baada ya kozi

• Ikiwa mwitikio ni dhaifu: toa chanjo za kando na nyongeza za ziada

Ufanisi dhidi ya homa ya ini A:

• Ubadilishaji wa serolojia kwa >99% baada ya dozi ya 2

• Sawa na chanjo ya homa ya ini A peke yake

Ufanisi dhidi ya homa ya ini B:

• Ubadilishaji wa serolojia kwa >95% baada ya kozi kamili

• Sawa na chanjo ya homa ya ini B peke yake

Ratiba ya haraka:

• Kinga ya homa ya ini A: >98% baada ya dozi ya 3 (siku ya 21)

• Kinga ya homa ya ini B: ~80% baada ya dozi ya 3 (siku ya 21), >95% baada ya nyongeza (miezi 12)

Muda wa kinga:

• Kama chanjo za kando: kinga ya muda mrefu sana baada ya kozi kamili

• HepA: ≥25 miaka; HepB: ≥30 miaka (immunological memory)

Chanjo nyingine:

• Twinrix inaweza kutolewa pamoja na chanjo nyingine za wasafiri (homa ya manjano, typhoid, meningococcal, kichaa cha mbwa) katika sehemu tofauti

Immunoglobulini:

• IG ya homa ya ini A na HBIG zinaweza kutolewa pamoja na Twinrix katika sehemu nyingine kwa kinga ya dharura

Dawa:

• Hakuna mwingiliano unaojulikana

Pregnancy: Twinrix® (inactivated hepatitis A + recombinant hepatitis B) has limited data in pregnancy. Both individual components (hepatitis A and hepatitis B vaccines) have established safety profiles in pregnancy. Hepatitis B vaccination is routinely recommended for pregnant women at risk of HBV infection. Hepatitis A vaccine may be administered during pregnancy when indicated. The theoretical risk from inactivated vaccines during pregnancy is negligible. Consider Twinrix® if both hepatitis A and B protection are needed and the travel timeline is tight.

Breastfeeding: Twinrix® (inactivated) is compatible with breastfeeding. Both hepatitis A and hepatitis B vaccines are inactivated and pose no risk to the breastfed infant. Inactivated vaccines do not replicate and cannot be transmitted through breast milk. No modification of breastfeeding schedule is required. Vaccination of breastfeeding mothers who require hepatitis A and/or B protection should not be deferred.

Pediatric use: Twinrix® is approved for individuals ≥18 years in the United States. A pediatric/adolescent formulation (Twinrix Junior®) is available in some markets for children aged 1–15 years. For children under the approved age, individual hepatitis A and hepatitis B vaccines should be administered separately. Hepatitis A vaccine is recommended from 12 months of age; hepatitis B vaccine is given as part of the routine birth dose series. Children traveling internationally should ideally complete both vaccine series before travel.

Older adults (≥65 years): Twinrix® can be administered to older adults. Immune response to both hepatitis A and hepatitis B components may be diminished in older adults due to immunosenescence. For hepatitis B specifically, seroconversion rates decline with age (approximately 75% in adults ≥60 vs >95% in young adults). Post-vaccination serological testing (anti-HBs) may be considered for older adults at ongoing risk. A higher-dose hepatitis B vaccine (Heplisav-B®) may be used separately if enhanced HBV response is desired.

Ratiba za Twinrix:

• Kawaida: miezi 0, 1, 6 (dozi 3)

• Haraka: siku 0, 7, 21 + nyongeza miezi 12 (dozi 4 — kinga ya haraka kwa wasafiri)

Upatikanaji:

• Inapatikana katika kliniki za usafiri za kibinafsi

• Bei: ~USD 50-80 kwa dozi katika Afrika Mashariki

Hifadhi:

• +2°C hadi +8°C — usigandishe